NASDAQ: EYENEyenovia Inc Stock
$1.09-0.04 (-3.54%)
Updated Apr 25, 2025
EYEN Price
$1.09
Fair Value Price
-$0.24
Market Cap
$3.09M
52 Week Low
$0.85
52 Week High
$124.80
P/E
-0.02x
P/B
-0.24x
P/S
169.69x
PEG
N/A
Dividend Yield
N/A
Revenue
$57.34k
Earnings
-$49.82M
Gross Margin
-6,749.5%
Operating Margin
-82,555.47%
Profit Margin
-86,888.6%
Debt to Equity
-1.28
Operating Cash Flow
-$30M
Beta
0.98
Next Earnings
Jun 12, 2025
Ex-Dividend
N/A
Next Dividend
N/A
EYEN Overview
Eyenovia, Inc., a clinical stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print platform technology. The company focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. It focuses on the development of therapeutic indications for patients with progressive myopia and age-related near vision impairment or presbyopia indications; and microdose fixed combination ophthalmic pharmaceutical for mydriasis to address the eye exams with pupil dilation. The company's product candidates include MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); and MydCombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; and a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine and MicroLine in China and South Korea. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is headquartered in New York, New York.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine EYEN's potential to beat the market
- EYEN doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
EYEN
RankedUnranked of 460
RankedUnranked of 460
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.85 | A | |
| $8.18 | A | |
| $23.45 | A |
Be the first to know about important EYEN news, forecast changes, insider trades & much more!
EYEN News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how EYEN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
EYEN ($1.09) is overvalued by 556.93% relative to our estimate of its Fair Value price of -$0.24 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
EYEN ($1.09) is not significantly undervalued (556.93%) relative to our estimate of its Fair Value price of -$0.24 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
EYEN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more EYEN due diligence checks available for Premium users.
Valuation
EYEN fair value
Fair Value of EYEN stock based on Discounted Cash Flow (DCF)
Price
$1.09
Fair Value
-$0.24
Undervalued by
556.93%
EYEN ($1.09) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
EYEN ($1.09) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
EYEN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
EYEN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.02x
Industry
-157.91x
Market
29.65x
EYEN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.24x
Industry
4.26x
EYEN's financial health
Profit margin
Revenue
$28.1k
Net Income
-$20.0M
Profit Margin
-71,031.1%
EYEN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
EYEN's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$3.7M
Liabilities
$16.8M
Debt to equity
-1.28
EYEN's short-term liabilities ($16.05M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
EYEN's short-term assets ($2.77M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
EYEN's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
EYEN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$6.1M
Investing
-$1.0
Financing
$1.0M
EYEN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
EYEN vs Biotech Stocks
Eyenovia Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.